Abstract:Aims: Cardiotoxicity is one major reason why drugs do not enter or are withdrawn from the market. Thus, approaches are required to predict cardiotoxicity with high specificity and sensitivity. Ideally, such methods should be performed within intact cardiac tissue with high relevance for humans and detect acute and chronic side effects on electrophysiological behaviour, contractility, and tissue structure in an unbiased manner. Herein, we evaluate healthy pig myocardial slices and biomimetic cultivation setups (BMCS) as a new cardiotoxicity screening approach. Methods and results: Pig left ventricular samples were cut into slices and spanned into BMCS with continuous electrical pacing and online force recording. Automated stimulation protocols were established to determine the force-frequency relationship (FFR), frequency dependence of contraction duration, effective refractory period (ERP), and pacing threshold. Slices generated 1.3 ± 0.14 mN/mm2 force at 0.5 Hz electrical pacing and showed a positive FFR and a shortening of contraction duration with increasing pacing rates. Approximately 62% of slices were able to contract for at least 6 days while showing stable ERP, contraction duration-frequency relationship, and preserved cardiac structure confirmed by confocal imaging and X-ray diffraction analysis. We used specific blockers of the most important cardiac ion channels to determine which analysis parameters are influenced. To validate our approach, we tested five drug candidates selected from the Comprehensive in vitro Proarrhythmia Assay list as well as acetylsalicylic acid and DMSO as controls in a blinded manner in three independent laboratories. We were able to detect all arrhythmic drugs and their respective mode of action on cardiac tissue including inhibition of Na+, Ca2+, and hERG channels as well as Na+/Ca2+ exchanger. Conclusion: We systematically evaluate this approach for cardiotoxicity screening, which is of high relevance for humans and can be upscaled to medium-throughput screening. Thus, our approach will improve the predictive value and efficiency of preclinical cardiotoxicity screening.

Report and Recommendations of the Workshop of the European Centre for the Validation of Alternative Methods for Drug-Induced Cardiotoxicity

Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms

Consensus report on the future of animal-free systemic toxicity testing

International Harmonization and Cooperation in the Validation of Alternative Methods

Update of the DevTox Data Database for Harmonized Risk Assessment and Alternative Methodologies in Developmental Toxicology: Report of the 9th Berlin Workshop on Developmental Toxicity.

Current EU regulatory requirements for the assessment of chemicals and cosmetic products: challenges and opportunities for introducing new approach methodologies

A comprehensive view on mechanistic approaches for cancer risk assessment of non-genotoxic agrochemicals

Thirty years of telemetry-based data acquisition for cardiovascular drug safety evaluation: Applications and optimization

Alternative strategies in cardiac preclinical research and new clinical trial formats

State of the science on alternatives to animal testing and integration of testing strategies for food safety assessments: Workshop proceedings

Examining animal testing for risk assessment: A WC-12 workshop report

Assessing Drug-Induced Mitochondrial Toxicity in Cardiomyocytes: Implications for Preclinical Cardiac Safety Evaluation

Continuing Harmonization of Terminology and Innovations for Methodologies in Developmental Toxicology: Report of the 8th Berlin Workshop on Developmental Toxicity, 14–16 May 2014

Review of Current and “omics” Methods for Assessing the Toxicity (genotoxicity, Teratogenicity and Nephrotoxicity) of Herbal Medicines and Mushrooms

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

The benefits of validation of methods for toxicity testing outweigh its costs

Contractility measurements for cardiotoxicity screening with ventricular myocardial slices of pigs

25th anniversary of the Berlin workshop on developmental toxicology: DevTox database update, challenges in risk assessment of developmental neurotoxicity and alternative methodologies in bone development and growth.

Opportunities for Microphysiological Systems in Toxicity Testing of New Drug Modalities

Setting the stage for next-generation risk assessment with non-animal approaches: the EU-ToxRisk project experience

Considerations for the Identification and Conveyance of Clinical Pathology Findings in Preclinical Toxicity Studies: Results From the 9th ESTP International Expert Workshop